Amplify Seymour Cannabis ETF (CNBS)

The Amplify Seymour Cannabis ETF (NASDAQ: CNBS) is an exchange-traded fund that holds shares of companies involved in the cultivation, distribution, retail, and support services of cannabis and hemp products. It tracks companies operating primarily in North America, where state-level legalization has created a nascent but rapidly scaling industry.

The origin of cannabis as an investable sector

Cannabis was illegal at the federal level in the United States until recently and remains so in many jurisdictions worldwide. But starting in 1996 when California voted to allow medical cannabis, states began carving out exceptions. By the early 2020s, roughly half of US states had legalized medical cannabis, and several had legalised it entirely for adult use. This created a legal market in a patchwork of state regimes.

The cannabis sector as an investment emerged from this regulatory opening. Amplify Seymour Cannabis ETF, launched in 2017, was among the first and most prominent vehicles designed to capture the growth of a legal, regulated cannabis industry. The fund tracks the Seymour Cannabis Index, a proprietary index that identifies and weights companies with meaningful revenue exposure to cannabis and hemp.

From launch through the late 2010s, the fund rode a wave of optimism — federal legalization seemed inevitable, the US market was expanding rapidly, and Canada had already legalized federally in 2018. But by the early 2020s, several headwinds emerged. Federal legalization did not materialise, banking restrictions persisted, and the Canadian cannabis market proved far smaller and more competitive than early forecasts.

What CNBS holds and the business segments

CNBS holds roughly 30–50 companies across the cannabis value chain. Growers and cultivators — companies that operate licensed farms and greenhouses — form the backbone. Retailers and distributors who sell directly to consumers or other businesses are well represented. Ancillary companies that do not touch the plant itself (packaging, testing labs, software platforms, real-estate operators) also figure in the portfolio. The index maintains no single holding above a modest weight, aiming for diversification across the emerging industry.

Most holdings are Canadian large-cap companies that started in the federally legal Canadian market (Canopy Growth, Tilray, Cronos) or US companies operating in state-legal markets under strict compliance rules (Curaleaf, Trulieve, Verano). Some holdings are ancillary plays without direct cannabis operations — for example, a real-estate company that owns and leases growing facilities.

The fund excludes pure-play illegal-market operators, so it does not hold unlicensed cultivators or black-market distributors. This boundary is legally and operationally important: US banks and brokers will not finance illegal operations, so CNBS is restricted to regulated entities.

Cyclicality and the regulatory boom-bust pattern

Cannabis investing is almost purely a regulatory play. The industry does not have a natural competitive equilibrium; its size and profitability depend almost entirely on the legal regime in force. When a state legalises adult-use cannabis, demand booms and prices are high. Existing cultivators race to expand; new entrants flood the market. Prices eventually collapse as supply exceeds demand, and many competitors exit. This boom-bust pattern is not normal business cyclicality — it is driven by regime change.

CNBS captured the boom phase from 2017–2019 when state legalisation was accelerating and optimism about federal legality was high. The bust phase arrived in the early 2020s when market oversupply, banking barriers, and delayed federal action caused share prices to plummet. The fund fell sharply as cannabis stocks cratered, because the entire sector had become unloved despite some states continuing to expand access.

The key risk is asymmetric: if federal legality comes and banking barriers fall, capital floods in and cannabis companies can consolidate and scale. If federal legality does not come and state-level prohibition re-expands, the entire industry could face margin compression or worse. CNBS holders are betting on the former, not the latter.

Structural challenges facing cannabis companies

Cannabis companies face headwinds that traditional consumer-goods companies do not. Section 280E of the US tax code disallows deductions of ordinary business expenses for businesses trafficking in controlled substances, even if state-legal. This inflates effective tax rates and suppresses margins. Many banks will not lend to cannabis businesses, forcing them to rely on equity capital and high-cost debt. Interstate commerce is illegal, so a California cultivator cannot easily export to Nevada, fragmenting the market into dozens of isolated regional monopolies with high prices.

These are not temporary frictions; they are structural consequences of cannabis remaining federally prohibited. As long as that is true, cannabis companies will be perpetually more expensive to operate than equivalent businesses in legalised industries. If federal prohibition ends, much of that friction disappears overnight.

The Canadian and international exposure

CNBS holds a meaningful weight in Canadian cannabis companies, which operate in a federally legalised market. Canadian cannabis is subject to none of the Section 280E tax issues, interstate barriers, or banking restrictions that plague US operators. But the Canadian market itself has proven much smaller and slower-growing than expected. Companies like Canopy Growth that spent billions building capacity found themselves in a glutted, low-margin market where illegal sellers still capture a large share of consumption.

The Canadian experience is a cautionary tale: legality alone does not guarantee profitable growth if supply outpaces demand and consumer preferences favour other options.

How CNBS tracks the market

CNBS uses the Seymour Cannabis Index, which is curated by Amplify Investments and rebalanced quarterly. The index is not market-cap-weighted; it applies custom rules to screen for cannabis-revenue exposure and assigns weights that reflect both company size and diversity. This approach aims to avoid concentration in a few mega-cap names but also introduces index-management risk — the rules themselves can become outdated or misaligned with market conditions.

How to research CNBS

Start with Amplify’s fact sheet and the current index methodology. Review the top ten holdings to understand exposure to growers, retailers, and ancillaries. Monitor industry data from firms like BDSA and MG Intelligence, which track sales, pricing, and market share in state and provincial cannabis markets. Follow federal legislative developments (is legality getting closer or farther away?) and banking changes (are traditional lenders opening cannabis accounts?). Finally, compare CNBS’s performance to individual cannabis stocks you are familiar with to see whether the fund’s custom indexing is adding or subtracting value relative to a simple market-cap-weighted approach.